BRAF Inhibitors in Non-Small Cell Lung Cancer

SIMPLE SUMMARY: The identification of BRAF mutations in 1.5–3.5% of NSCLC patients represents a step forward towards new targeted agents for tackling NSCLC. The positive results and favourable safety profile observed with the combination of dabrafenib and trametinib for the treatment of BRAF V600E m...

Descripción completa

Detalles Bibliográficos
Autores principales: Sforza, Vincenzo, Palumbo, Giuliano, Cascetta, Priscilla, Carillio, Guido, Manzo, Anna, Montanino, Agnese, Sandomenico, Claudia, Costanzo, Raffaele, Esposito, Giovanna, Laudato, Francesca, Damiano, Simona, Forte, Cira Antonietta, Frosini, Giulia, Farese, Stefano, Piccirillo, Maria Carmela, Pascarella, Giacomo, Normanno, Nicola, Morabito, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562258/
https://www.ncbi.nlm.nih.gov/pubmed/36230797
http://dx.doi.org/10.3390/cancers14194863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562258/
https://www.ncbi.nlm.nih.gov/pubmed/36230797
http://dx.doi.org/10.3390/cancers14194863

Ejemplares similares